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Context: Effects of vitamin D repletion in young people with low vitamin D status have not been
investigated so far.
Objective:We evaluated the effect of a single massive dose of cholecalciferol on calcium metab-
olism at 3, 15, and 30 d, compared to baseline.
Design and Setting:We conducted a prospective intervention study in an ambulatory care setting.
Participants: Forty-eight young subjects with vitamin D deficiency participated in the study.
Intervention: A single oral dose of 600,000 IU of cholecalciferol was administered to each subject.
Main Outcome Measures:We evaluated serum changes of 25-hydroxyvitamin D [25(OH)D], 1,25-
dihydroxyvitamin D, calcium, and PTH induced by a single load of cholecalciferol.
Results: The 25(OH)D level was 15.8  6.5 ng/ml at baseline and became 77.2  30.5 ng/ml at 3 d
(P  0.001) and 62.4  26.1 ng/ml at 30 d (P  0.001). PTH levels concomitantly decreased from
53.0  20.1 to 38.6  17.2 pg/ml at 3 d and to 43.4  14.0 pg/ml at 30 d (P  0.001 for both). The
trends were maintained in a subgroup followed up to 90 d (P  0.001). Mean serum Ca and P
significantly increased compared to baseline, whereas serum Mg decreased at 3 d. 1,25-Dihy-
droxyvitamin D significantly increased from 46.8 18.9 to 97.8 38.3 pg/ml at 3 d (P 0.001) and
to 59.5  27.3 pg/ml at 60 d (P  0.05).
Conclusions:A single oral dose of 600,000 IU of cholecalciferol rapidly enhances 25(OH)D and reduces
PTH in young people with vitamin D deficiency. (J Clin Endocrinol Metab 95: 4771–4777, 2010)
Vitamin D depletion has been reported as a very com-mon condition worldwide, with many implications
for health (1–4). Although elderly institutionalized pa-
tients are at high risk, several studies have also shown a
high prevalence of vitamin D deficiency among healthy
postmenopausal free-living women and among the gen-
eral adult population (5–13). Well-known consequences
of hypovitaminosis D are secondary hyperparathyroid-
ism, bone loss, proximal muscle weakness, increase in
body sway, falls, and fractures (7).Moreover, nonskeletal
consequences of vitamin D deficiency have been associ-
ated with an enhanced risk of chronic disease and cancer
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(1–4, 14), and the association between intake of vitamin
D supplements and decrease in all-cause mortality has
been reported (15). Sunlight exposure iswidely recognized
as the main source of vitamin D, but prolonged sun ex-
posure is usually discouraged because of an increased risk
of skin cancer. A recent evidence-based review (16) actu-
ally recognized that a threshold of sun exposure sufficient
to maintain a healthy vitamin D status without measur-
able cancer risk is difficult to define.Hence, current guide-
lines recommend a daily intake of at least 1000 IU of vi-
taminD.To reach this supplementation, an adequate food
fortification and oral supplementation are widely sug-
gested (1, 17). However, clinical recommendations con-
cerning the optimal dose and the frequency of adminis-
tration of vitamin D to achieve and maintain the target
vitaminD serum level [usually expressed in termsof serum
25-hydroxyvitamin D or 25(OH)D] and to decrease the
PTH secretion are still lacking. Themajority of the studies
(18–22) investigated the response of serum 25(OH)D to
large doses of cholecalciferol in the elderly, which are con-
sidered the population at highest risk of vitamin D defi-
ciency. Trivedi et al. (18) found that a single oral 100,000
IU dose of cholecalciferol is safe and effective in reducing
fractures in community-dwelling people over age 65 yr.
Ilahi et al. (19) suggested that a single oral dose of 100,000
IU of cholecalciferol every 2months is useful in increasing
and maintaining 25(OH)D concentration above baseline
in the elderly. Recent data from our group (20) reported
the greater potency (and the safety) of a single, large, oral
300,000-IU dose of cholecalciferol, compared with ergo-
calciferol, in enhancing serum 25(OH)D concentration
with concomitant decrease in PTH secretion. Bacon et al.
(22) reported in the elderly a normalization of 25(OH)D
values 1 month after an oral dose of 500,000 IU of chole-
calciferol.However, to our knowledge, despite several pa-
pers carriedout in elderly subjects, data onyounger people
are still limited. In particular, Tangpricha et al. (23) ob-
served an increase of 150% in serum 25(OH)D and a
decrease of 25% in serum PTH concentration from base-
line to the 12th week in healthy adults who daily received
orange juice fortified with 1000 IU of vitamin D3. We
instead performed a prospective intervention study to
evaluate the effect of a single loading oral dose of chole-
calciferol (600,000 IU) on the vitamin D-PTH axis in a
sample of young subjects with vitamin D deficiency.
Subjects and Methods
We studied 48 free-living subjects (35 females and 13 males;
mean age SD, 36.04 8.46 yr; age range, 25–56 yr; bodymass
index, 24  3.52 kg/m2) with limited sun exposure because of
poor tolerability, skin cancer, or other skin diseases. None of
them had diseases or took drugs affecting bone metabolism, nor
did they consume calcium or vitamin D supplements. The study
was performed between January and March 2009. All subjects
were placed on a standardized diet with 1000–1500 mg of ele-
mental calcium per day starting 2 months before the beginning
of the study. All participants received a single oral dose of
600,000 IU of cholecalciferol, which equals two vials of com-
mercially available cholecalciferol in Italy. Fasting blood sam-
ples were collected at baseline and 3, 15, and 30 d after chole-
calciferol administration in all participants. A subgroup of 20
female subjects (mean age, 33.2  6 yr; range, 25–50 yr; body
mass index, 23.84.01kg/m2) agreed to continue the follow-up
and were also assessed at 60 and 90 d. In all subjects, the fol-
lowing serum biochemical parameters were measured: total cal-
cium (Ca), phosphorus (P), magnesium (Mg), 25(OH)D, and
PTH. In the subgroup of 20 subjectswhowere followed for 90 d,
serum 1,25-dihydroxyvitamin D [1,25(OH)2D] levels were also
assessed. Moreover, in this subgroup of subjects, serum 25-hy-
droxyvitaminD3 [25(OH)D3]wasmeasuredwithHPLCatbase-
line and at 3 and 60 d to selectively measure 25(OH)D3, but not
other vitamin D metabolites. In 28 participants, a morning fast-
ing 3-h urinary collectionwas also taken tomeasure calcium and
magnesium excretion; tubular reabsorption was expressed as
excretion per unit of creatinine clearance [mg/dl of glomerular
filtration rate (GFR)]. Serum 25(OH)D concentrations were
measured by RIA (Diasorin Inc., Stillwater, MN); the intra- and
interassay coefficients of variation (CVs) were 8.1 and 10.2%,
respectively. Serum 25(OH)D3 level was measured by solid
phase extraction/isocraticHPLC-reversephasewith spectropho-
tometric detection at 265 nmUV (Eureka Lab Division, Chiara-
valle, Ancona, Italy). The sensitivity of the method was 2 ng/ml
(24). Serum 1,25(OH)2D concentrations were determined by
RIA (IDS; Nordic, Herlev, Denmark); the intra- and interassay
CVs were 9.3 and 9.6%, respectively. Serum PTH levels were
assessed by IRMA (N-tact PTHSP; Diasorin Inc.); the intra- and
interassay CVs were 3 and 5.5%, respectively. Blood samples
were then stored at70C, and the assayswere performed in one
batch at the end of the study.
Written, informed consent was obtained from all partici-
pants. The protocol was approved by the “Sapienza” University
of Rome Ethics Committee.
Statistics
Patient’s biochemical measures according to time from vitamin
D load were reported as mean SD, and differences were assessed
via repeated measurements ANOVA models. Comparisons be-
tweengroupsatbaselineandbetweenbaselineandfollow-upvalues
at each time point were performed by unpaired and paired t test.
Significance was set at a P value of 0.05. SigmaStat version 3.5
(Systat Software, London,UK)wasused for statistical calculations.
Results
Biochemical parameters of all the participants at baseline
and at all time points are reported in Table 1. Basal values
of 25(OH)D and PTH did not differ between the whole
group and the 20 subjects followed up to 90 d.
Figure 1A shows changes in serum 25(OH)D levels in-
duced by vitaminD supplementation in thewhole sample.
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Wefounda significant change in25(OH)D levels through-
out the entire observation period [P 0.001, by repeated
measures (RM) ANOVA]. In particular, a sharp and sig-
nificant increase was observed already at 3 d, attaining
average values of 77.1 30.5 ng/ml (P 0.001), with an
absolute increment abovebaselineof61.328ng/ml (P
0.001). Subsequently, there was a slow but not significant
decrease; at the end of the observation period, mean
25(OH)Dserumlevels, aswell as the30-dbasaldifference,
remained significantly higher than baseline (P  0.001)
(Fig. 1, A and B). Noteworthy, the highest 25(OH)D level
achievedat the thirdday ina female subjectwas136ng/ml.
Vitamin D load induced a significant decrease in serum
PTH concentration (P 0.001, by RM ANOVA), which
FIG. 1. Effect of vitamin D supplementation on 25(OH)D serum changes. A and B, Mean values and respective basal difference of serum 25(OH)D
at each time point in the whole sample (n  48). B, Mean  SE values of 25(OH)D basal difference at 3, 15, and 30 d were 61.4  4, 60.7  3.8,
and 46.7  23.9 ng/ml, respectively. *, P  0.001 vs. baseline. C and D, Mean values and the respective basal difference of serum 25(OH)D at
each time point in the subgroup (n  20). D, Mean  SE values of 25(OH)D basal difference at 3, 15, 30, 60, and 90 d were 56.5  3.4, 53.7 
3.6, 46.3  3, 25.6  2, and 14.7  3.3 ng/ml, respectively. *, P  0.001 vs. baseline. The dashed lines (A and C) represent the threshold level for
vitamin D adequacy, settled at 32 ng/ml.
TABLE 1. Biochemical parameters of all subjects at each time point
Parameter Baseline 3 d 15 d 30 d 60 d 90 d Pa
Ca (mg/dl) A 9.3  0.4 9.5  0.3 9.4  0.3 9.4  0.3 0.05
B 9.3  0.3 9.5  0.3 9.4  0.3 9.4  0.3 9.4  0.3 9.5  0.4 NS
P (mg/dl) A 3.8  0.6 4.0  0.6 3.8  0.5 3.8  0.6 0.01
B 3.5  0.4 3.8  0.6 3.6  0.4 3.6  0.6 3.4  0.5 3.5  0.5 0.01
Mg (mg/dl) A 2.0  0.2 1.9  0.2 2.0  0.2 2.0  0.2 0.001
B 1.8  0.1 1.7  0.1 1.8  0.1 1.8  0.1 1.9  0.2 1.8  0.1 0.05
25(OH)D (ng/ml) A 15.8  6.5 77.2  30.5 76.5  27.9 62.4  26.1 0.001
B 17.2  6.3 73.7  16.9 70.9  14.9 63.5  12.5 42.8  8.9 31.9  12.6 0.001
PTH (pg/ml) A 53.0  20.1 38.6  17.2 40.6  15.8 43.4  14 0.001
B 57.0  21.6 39.2  15.9 36.7  14.5 39.2  13 42.8  19.1 37.7  15.1 0.001
1,25(OH)2D (pg/ml) A
B 46.8  18.9 97.8  38.3 90.7  46.9 74.9  36.8 59.5  27.3 52.9  23.3 0.001
CaEx (mg/dl GFR) C 0.08  0.06 0.10  0.08 0.10  0.05 0.08  0.04 0.05
MgEx (mg/dl GFR) C 0.04  0.02 0.06  0.03 0.05  0.02 0.05  0.03 NS
All values are expressed as mean  SD. A, Whole sample (n  48); B, subgroup of subjects followed up to 90 d (n  20); C, subgroup of subjects
collecting urine samples (n  28); CaEx, calcium excretion; MgEx, magnesium excretion; NS, not significant.
a RM ANOVA.
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was already significant at 3 d (P  0.001). Thereafter,
PTH values slowly increased, but at each time point they
remained significantly lower comparedwith baseline (P
0.001) (data not shown).
SerumCaandP levels significantly changed throughout
the entire period (P 0.05 and P 0.01, respectively, by
RM ANOVA) (Table 1). However, the increase with re-
spect to baseline was significant only at 3 d after supple-
mentation (Ca, 0.1  0.3 mg/dl; P, 0.2  0.5 mg/dl; P 
0.01 for both). Moreover, there was a significant change
in Mg serum levels (P  0.001), whose values were sig-
nificantly reduced only on the third day (0.05  0.1
mg/dl, P  0.01). In subjects collecting urine samples,
calcium excretion significantly changed (P  0.05). The
increase of calcium excretion was significant both 3 d
(0.03 0.04mg/dl GFR; P 0.01) and 15 d (0.02 0.04
mg/dl GFR; P  0.05) after cholecalciferol supplementa-
tion. Magnesium excretion was significantly increased
only at 3 d (0.02  0.02 mg/dl GFR; P  0.01).
The changes of serum 25(OH)D levels in the subgroup
of 20 subjects followed up to 90 d were similar to those
found in the sample as a whole (Fig. 1, C and D). In par-
ticular, mean values of 25(OH)D were still significantly
higher with respect to baseline at both 60 and 90 d. Note-
worthy, at 90 d, nine of 20 patients had 25(OH)D levels
over the threshold of vitamin D sufficiency. The increase
of serum 25(OH)D at 3 d was confirmed using a HPLC
assay, which separates 25(OH)D3 from all other vitamin
Dmetabolites. Indeed, 25(OH)D3 serum levels at 3 dwere
significantly higher with respect to baseline (56.6  15.9
vs. 12.7  6.9 ng/ml; P  0.001); at 60 d serum levels
decreased, mean values being still significantly higher than
baseline (28.5 8.1 mg/dl; P 0.001). Percentage changes
with respect to baseline between the two methods were not
significantly different at 3 and 60 d (data not shown). A
significant positive correlation was found between HPLC
and RIA assays (r 0.81; P 0.0001) (Fig. 2).
The concomitant changes of PTH and 1,25(OH)2D se-
rum levels, expressed as absolute differences from basal
values, are reported in Fig. 3. We found a significant de-
creaseof serumPTHalreadyat3d (P0.001).The lowest
values were reached at 15 d (20.3  17.8 pg/ml; P 
0.001). The decrease was statistically significant through-
out the entire period of observation. The reduction of se-
rum PTH was mirrored by the concomitant increase in
1,25(OH)2D values (Table 1). In fact, we observed a rapid
increase of 1,25(OH)2D levels at 3 d (P  0.001). This
increase was statistically significant up to 60 d, whereas at
90 d 1,25(OH)2D levels returned to baseline.
Changes in Ca, P, and Mg levels in the subgroup fol-
lowed up to 90 d were similar to those observed in the
whole sample,with a significant increase inCaandP levels
after 3 d (P  0.01) and a concomitant significant Mg
decrease (P  0.50) (data not shown).
Discussion
Available evidence in the elderly suggests that at least 800-
1000 IU of vitamin D per day are needed to achieve mean
serum 25(OH)D levels of 32 ng/ml (25). This value, asso-
ciated with the optimal calcium absorptive performance
(26), is currently considered by many authors as the
threshold of adequate vitaminD status (25, 27–29).How-
ever, there are limited and nonconclusive data about the
optimal dose and dosing intervals needed to achieve and
maintain these levels and to reduce secondary hyperpara-
thyroidism (30). Several studies reported safety and effi-
cacy of supplementation with large doses of vitamin D,
FIG. 2. Correlation between the concentration of 25(OH)D assessed
by HPLC method and RIA assay.
FIG. 3. Effect of vitamin D supplementation on the basal difference of
serum 1,25(OH)2D (upper panel) and of PTH (lower panel) in the
subgroup of 20 subjects. Mean  SE values of 1,25(OH)2D basal
difference at 3, 15, 30, 60, and 90 d were 51  9, 43.8  9.3, 28.2 
7.5, 12.7  5.5, and 6.1  4.7 pg/ml, respectively. Mean  SE values
of PTH basal difference at 3, 15, 30, 60, and 90 d were 17.8  3.3,
20.3  4, 17.8  3.4, 14.2  4, and 19.3  2.7 pg/ml,
respectively. *, P  0.001; **, P  0.01; ***, P  0.05.
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particularly in the elderly (18–22, 31). It has been sug-
gested that a single high dose of cholecalciferol is effective
in rapidly increasing 25(OH)D levels, namely in patients
with severe vitamin D deficiency. Moreover, higher inter-
mittent doses of cholecalciferol were proposed to improve
adherence to treatment (20, 22, 25). New guidelines
claimed the reevaluation of the upper limit of safe vitamin
D daily intake, with a trend to shift to 2000 IU/d (1).
In this study, we evaluated the effect of a single very
large oral dose of cholecalciferol (600,000 IU) on serum
levels of 25(OH)D and other calciotropic hormones in
young subjects with vitamin D deficiency. Our results
demonstrate that an oral dose of 600,000 IU of cholecal-
ciferol is able to rapidly increase serum 25(OH)D levels
in patients with severe vitamin D depletion. A peak of
25(OH)D concentration was already attained as soon as
3 d after vitamin D administration, probably due to the
strikingly higher dose employed compared with previous
reports (20). Remarkable increments of 25(OH)D serum
levels were also attained at 3 d when 300,000 IU of chole-
calciferol were given to elderly subjects (20). Noteworthy,
the highest value attained in the present study by an indi-
vidual subject was 136 ng/ml, which is well below the
widely accepted toxic blood levels of 200 ng/ml (32). This
result was likely due to the low pretreatment vitamin D
statusof our sample.Moreover, 25(OH)D levels remained
significantly higher than baseline up to 30 d, and in the
subgroup of 20 subjects followed up to 90 d, 25(OH)D
basal difference was still significant at 90 d. In this group,
at the end of observation, half of the patients had
25(OH)D levels still over 32 ng/ml. Overall, our findings
demonstrate that a high oral dose of cholecalciferol rap-
idly enhances andmaintains adequate 25(OH)D levels up
to90dafter administration inyoung subjectswithvitamin
D deficiency. These results are in line with data obtained
in elderly subjects and probably rely on a rapid absorption
and conversion of the oral load of cholecalciferol to the
25-hydroxy metabolite. Heaney et al. (31) demonstrated
that vitamin D administration induces a biphasic re-
sponse, with a rapid increase of serum 25(OH)D at low
serumvitaminD3 concentrations and a slower response at
higher levels. Hence, we can hypothesize that the huge
increase of 25(OH)D levels after supplementation could
probably be due to the low basal vitamin D3 concentra-
tion. Ilahi et al. (19) also reported a peak of 25(OH)D
concentration 7 d after a single oral dose of 100,000 IU of
cholecalciferol, whereas others obtained similar results 1
month after giving an oral dose of 500,000 IU of chole-
calciferol to subjectswith initial 25OHDlevels of 20ng/ml
or less (22, 33).However, the authorsdidnot give anydata
at 3–10 d after cholecalciferol loading.On the other hand,
a single im dose of 600,000 IU of cholecalciferol may en-
hance 25(OH)D levels above the threshold of sufficiency
only at 4 months in subjects with vitamin D deficiency
(34). This finding confirms that, faced with the physio-
logical skin production, the oral administration is a valu-
able alternative route of vitamin D supplementation. This
is also supportedbyprevious results fromourgroup show-
ing that a dose of 300,000 IU of cholecalciferol given
orally but not im can sharply and significantly increase
25(OH)D levels in vitaminD-deficient elderly people (20).
In that study, the highest 25(OH)D concentration was
found at 30 d, and it remained significantly higher than
baseline up to 2 months. We can therefore conclude that
both 600,000 and 300,000 IU of oral cholecalciferol de-
termine a sharp and significant increase in 25(OH)D lev-
els, maintaining adequate vitamin D status for at least 2
months. Moreover, a single oral dose of 600,000 IU ad-
ministered to younger and less deficient subjects induced
a faster increase of 25(OH)D levels, and a good vitaminD
status was maintained up to 90 d.
The results obtained by the RIA method were further
strengthened by those obtained with HPLC, separating
25(OH)D3 from all other vitamin D metabolites. Indeed,
the huge increase measured by RIA at 3 d is confirmed by
the HPLC results. However, we found an apparent dis-
crepancy between the mean 25(OH)D levels measured by
RIA and 25(OH)D3 assessed byHPLC. Indeed, looking at
Fig. 2, it is apparent that RIAmeasurement overestimated
values below 40 ng/ml, whereas it underestimated values
above 40 ng/ml with respect to HPLC. Such a difference
was not significant, namely at 3 d, and it might be due to
the small size of the sample assessed by both methods.
Also, considering this limit,we showed that a loading dose
of oral cholecalciferol rapidly and significantly improved
vitamin D status as soon as 3 d.
The significant increase in serumcalcium levels 3dafter
supplementation could probably depend on an increase of
calcium absorption due to the rise in 25(OH)D values (26).
This hypothesis is confirmed by a significant increase in
urinary calcium excretion at 3 d, because intestinal cal-
cium daily absorption implicitly equates to urinary cal-
ciumdaily excretion (32).However, urinary datawere not
collected in all theparticipants andunfortunatelywerenot
informative about the effect of a very large dose of chole-
calciferol on 24-h calcium excretion, which is considered
a more sensitive indicator of vitamin D adverse effects
(35). It was also shown that a loading dose of 600,000 IU
of cholecalciferol rapidly enhanced magnesium urinary
excretion, probably because of the concomitant increase
in serum and urinary calcium levels. Indeed, renal mag-
nesium reabsorption is proportional to calcium excretion
anddependenton calcemia.Alternatively, the reduction in
renalMg reabsorption could be due to suppressed levels of
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PTH. However, noteworthy, serum Ca and Mg levels re-
mained in the physiological range during the entire obser-
vation period.
Significant reduction of serum PTH was observed al-
ready 3 d after administration of 600,000 IU of cholecal-
ciferol and persisted throughout the entire period of ob-
servation (30 d); in the group followed up to 90 d, serum
PTH levels were suppressed up to 3 months. On the other
hand, Diamond et al. (34) reported a significant decrease
in PTH levels only 12 months after administration of the
same amount of cholecalciferol by im route. In line with
our previous study, our current results confirm the greater
potency of an oral cholecalciferol load in rapidly reducing
PTH levels (20).
Also concerning 1,25(OH)2D serum changes, the cur-
rent results confirm our previous data (20). This finding
could be explained by a rapid conversion of the 25-hy-
droxy metabolite to 1,25(OH)2D because the initial sec-
ondary hyperparathyroidism promotes amarked increase
of 1,25(OH)2D levelswhen thesepatients ingest vitaminD
(36). It is also possible that a high concentration of serum
vitaminDmetabolitesmaydisplace 1,25(OH)2D from the
circulating vitamin D-binding protein (32). However, we
cannot exclude that the observed relevant change of
1,25(OH)2D levels at 3 d could depend on the relatively
lowspecificityof the employedassay, and these resultswill
require verification with a more specific assay.
We believe that our results have some clinical implica-
tions. The potency of a very large dose of cholecalciferol,
given orally, is an important finding in patients with high
risk of vitaminDdeficiency and high fracture risk. A rapid
vitamin D repletion is also desirable to prevent hypocal-
cemia in vitamin D-deficient patients before treatment
with iv bisphosphonates. Moreover, we believe that a
loading intermittent dose of cholecalciferol could also be
associated with a better adherence to treatment, also in
young people with vitamin D deficiency.
Ourdata regardingPTHchanges alsodeserve emphasis
because elevated PTH secretion due to vitamin D defi-
ciency is not only associatedwith increased bone turnover
and fracture risk, but may also result in increased mortal-
ity, at least in elderly vitamin D-deficient people (37). Al-
though our study was performed in young people, a rapid
reduction of PTH levels could be expected to occur also in
elderly patients (38). Moreover, the time-related pattern
of PTH change deserves interest because a marked de-
crease was already obtained at the third day and main-
tained until 90 d, despite no concomitant changes of serum
calcium levels. At the latter time point, the reduction of PTH
serum levels still persists, althoughCa and 1,25(OH)2D lev-
els returned to baseline values. This finding, in linewith pre-
vious results from our group (20, 39), supports the hypoth-
esis that25(OH)Dcouldalsohaveadirectrole inmodulating
PTH secretion, regardless of both 1,25(OH)2D and calcium
levels.
In conclusion, our results demonstrate that the admin-
istration of a single very large oral dose of 600,000 IU of
cholecalciferol is useful in rapidly and safely enhancing
25(OH)D levels and in reducing serumPTH in young peo-
ple with vitamin D deficiency.
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